Search research articles
Contact Us
Filters
Showing results (121-130 of 627) with videos related to
Page
of 63
Sort By:
Journal of the American Heart Association
|
December 2, 2021
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
Taha Sen, Jingwei Li, Brendon L Neuen, et al.
JAMA Cardiology
|
November 15, 2018
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study
Daniel Lindholm, Stefan K James, Katja Gabrysch, et al.
The American Journal of Cardiology
|
October 29, 2005
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes
Sunil V Rao, Kristi O'Grady, Karen S Pieper, et al.
Clinical Cardiology
|
February 4, 2010
Influence of clinical trial participation on subsequent antithrombin use
Bimal R Shah, Eric D Peterson, Anita Y Chen, et al.
Diabetes Care
|
June 20, 2022
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
Ele Ferrannini, Simona Baldi, Tiziana Scozzaro, et al.
Journal of the American College of Cardiology
|
January 12, 2001
Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion
M T Roe, E M Ohman, A C Maas, et al.
Circulation
|
November 15, 2017
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, et al.
JACC. Cardiovascular Interventions
|
November 19, 2013
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)
Hemal Gada, Ajay J Kirtane, William Newman, et al.
Diabetes, Obesity & Metabolism
|
August 17, 2021
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis
Kent Y Feng, JingWei Li, Juliana Ianus, et al.
American Heart Journal
|
July 1, 2008
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome
Steve Leung, Dianne Gallup, Kenneth W Mahaffey, et al.
Page
of 63
Search research articles
Search
Showing results (121-130 of 627) with videos related to
Sort By:
Page
of 63
Journal of the American Heart Association
|
December 2, 2021
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
Taha Sen, Jingwei Li, Brendon L Neuen, et al.
JAMA Cardiology
|
November 15, 2018
Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study
Daniel Lindholm, Stefan K James, Katja Gabrysch, et al.
The American Journal of Cardiology
|
October 29, 2005
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes
Sunil V Rao, Kristi O'Grady, Karen S Pieper, et al.
Clinical Cardiology
|
February 4, 2010
Influence of clinical trial participation on subsequent antithrombin use
Bimal R Shah, Eric D Peterson, Anita Y Chen, et al.
Diabetes Care
|
June 20, 2022
Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS)
Ele Ferrannini, Simona Baldi, Tiziana Scozzaro, et al.
Journal of the American College of Cardiology
|
January 12, 2001
Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion
M T Roe, E M Ohman, A C Maas, et al.
Circulation
|
November 15, 2017
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Kenneth W Mahaffey, Bruce Neal, Vlado Perkovic, et al.
JACC. Cardiovascular Interventions
|
November 19, 2013
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)
Hemal Gada, Ajay J Kirtane, William Newman, et al.
Diabetes, Obesity & Metabolism
|
August 17, 2021
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis
Kent Y Feng, JingWei Li, Juliana Ianus, et al.
American Heart Journal
|
July 1, 2008
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome
Steve Leung, Dianne Gallup, Kenneth W Mahaffey, et al.
Page
of 63